ADXN Share Price Performance
CHF 0.056
-0.00 (-0.71%)
65.0% undervalued intrinsic discount
CHF 0.16
Fair Value
Price CHF 0.056
AnalystConsensusTarget CHF 0.16
Fair ValueCHF 0.16
Share Pricen/a
Addex Therapeutics Ltd Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ADXN Community Narratives
AN
Fair Value CHF 0.16 65.0% undervalued intrinsic discount
CNS And Respiratory Therapies Will Unlock Expanding Global Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CNS And Respiratory Therapies Will Unlock Expanding Global Markets
Key Takeaways Differentiated CNS and respiratory pipeline, positive clinical progress, and strategic partnerships position Addex for long-term growth with stabilized earnings and mitigated R&D risk. Expanded intellectual property and global market trends enhance future out-licensing opportunities and scalability potential for Addex's novel therapies.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CHF 0.16
65.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
87.22% p.a.
Profit Margin
22.68%
Future PE
47.88x
Share price in 2028
CHF 0.18
Recently Updated Narratives
AN
CNS And Respiratory Therapies Will Unlock Expanding Global Markets
Fair Value: CHF 0.16 65.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Addex Therapeutics Ltd Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.042
- -294.77%
- -3,675.87%
- 0%
About ADXN
- Founded
- 2002
- Employees
- 2
- CEO
- WebsiteView website
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.